Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 283 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Relapsing-remitting Multiple Sclerosis Clear all
Completed Phase 2 Interventional

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

NCT00324506
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Mycophenolate Mofetil (CellCept)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Farmington Hills, Michigan • Buffalo, New York • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

NCT02342704
View directory record Official record
Conditions
Relapsing-Remitting Multiple Sclerosis
Interventions
natalizumab, fingolimod
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
12
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Port Charlotte, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 22, 2026, 1:09 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparison of Campath and Rebif Treatment on Cognition in Multiple Sclerosis (MS)

NCT00914758
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Washington Neuropsychology Research Group
Other
Eligibility
25 Years to 50 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
7
States / cities
Berkely, California • Lexington, Kentucky • Springfield, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2009 · Synced Oct 22, 2026, 1:09 AM EDT
Not yet recruiting Not applicable Interventional

Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis

NCT04768777
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction
Interventions
Behavioural intervention for physical activity for multiple sclerosis (BIPAMS)
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional Results available

Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis

NCT01006265
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ACT-128800 Dose 1, Placebo, ACT-128800 Dose 2, ACT-128800 Dose 3
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years to 55 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
25
States / cities
Scottsdale, Arizona • Tucson, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2025 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Natalizumab Re-Initiation of Dosing

NCT00306592
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BG00002 (natalizumab)
Biological
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
404 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
53
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2017 · Synced Oct 22, 2026, 1:09 AM EDT
Withdrawn No phase listed Observational

VALIDATE: Factor VIII Trending for MS Relapse

NCT04082468
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood sample collection for coagulation profile
Diagnostic Test
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

Safety of RG2077 in Patients With Multiple Sclerosis

NCT00076934
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
RG2077 (CTLA4-IgG4m)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy

NCT05028634
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Interventions
Tetanus, diphtheria, and acellular pertussis vaccine, Pneumococcal polysaccharide vaccine, Seasonal influenza vaccine
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
29
States / cities
Palo Alto, California • Colorado Springs, Colorado • Southington, Connecticut + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 3 Interventional Results available

Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).

NCT02525874
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Interventions
dimethyl fumarate
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Gilbert, Arizona • Long Beach, California • Ocala, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational

Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control

NCT01626248
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
John F. Foley, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

NCT00232193
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Clinically Isolated Syndrome
Interventions
Not listed
Lead sponsor
Providence Multiple Sclerosis Center
Other
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 22, 2011 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Phase 3 Interventional Results available

Maximizing Outcome of Multiple Sclerosis Transplantation

NCT03342638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 58 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Assessment of Deep Gray Matter Anatomic Changes in RRMS Patients Treated With Gilenya® With and Without Cognitive Impairment Over a 2 Year Period Using NeuroQuant, NeuroQuarc and ANAM

NCT05684016
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
NeuroQuant, Automated Neuropsychological Assessment Matrices, EDSS, Physical Examination
Other
Lead sponsor
George Washington University
Other
Eligibility
18 Years to 55 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional

Acute Intermittent Hypoxia in Persons With Multiple Sclerosis

NCT04280484
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Intermittent Hypoxia, Sham Hypoxia
Other
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational

Pilot Study to Assess Disease Stability in a Natalizumab to Dimethyl Fumarate Crossover Design

NCT01945359
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Rocky Mountain MS Research Group, LLC
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 1 Interventional

Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis

NCT00645749
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Helminth ova
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Oct 22, 2026, 1:09 AM EDT
Terminated Phase 1 Interventional

A Safety and Efficacy Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis

NCT01144351
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
ELND002, Placebo
Drug
Lead sponsor
Elan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
17
States / cities
Berkeley, California • Fresno, California • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Not applicable Interventional Results available

Light Therapy as Treatment for Fatigue in Multiple Sclerosis

NCT03060759
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Light Therapy box
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2020 · Synced Oct 22, 2026, 1:09 AM EDT
Recruiting Not applicable Interventional

Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis

NCT05964829
View directory record Official record
Conditions
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive
Interventions
Cionic Neural Sleeve NS-100, Walking Program
Device · Behavioral
Lead sponsor
Cionic, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Oct 22, 2026, 1:09 AM EDT
Completed Phase 2 Interventional

BEYOND Pilot Study

NCT00893217
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Betaseron (Interferon beta-1b, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
14
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2009 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

NCT00206635
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Interferon beta-1b (Betaseron, BAY86-5046)
Drug
Lead sponsor
Bayer
Industry
Eligibility
33 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
6
States / cities
Many Locations, Alabama • Many Locations, Arizona • Many Locations, California + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 22, 2026, 1:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Gene Expression Profiles in Multiple Sclerosis (MS)

NCT00704834
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Blood Draw
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2017
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 22, 2026, 1:09 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)

NCT04544436
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Ocrelizumab, Antihistamine, Methylprednisolone
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
864 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
25
States / cities
Cullman, Alabama • Homewood, Alabama • Phoenix, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 22, 2026, 1:09 AM EDT